{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:51Z","timestamp":1778889771834,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.critrevonc.2024.104551","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T07:49:50Z","timestamp":1730792990000},"page":"104551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review"],"prefix":"10.1016","volume":"205","author":[{"given":"Shaomei","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weicheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2024.104551_bib1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with richter syndrome: real-world study of the spanish chronic lymphocytic leukemia study group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2024.104551_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting bruton\u2019s tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.critrevonc.2024.104551_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classifcation of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.critrevonc.2024.104551_bib4","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.critrevonc.2024.104551_bib5","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104551_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/10428194.2022.2140286","article-title":"Richter transformation to aggressive plasmablastic neoplasm related to selection of a BTK-mutated clone in a patient with CLL\/SLL treated by ibrutinib","volume":"64","author":"Aqil","year":"2023","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.critrevonc.2024.104551_bib7","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11899-023-00701-y","article-title":"Richter transformation of chronic lymphocytic leukemia-are we making progress?","volume":"18","author":"Audil","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2024.104551_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104551_bib9","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo","year":"2008","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104551_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104551_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","article-title":"Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma","volume":"15","author":"Castillo","year":"2010","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.critrevonc.2024.104551_bib12","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I firstin-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2024.104551_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104551_bib14","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1007\/s00277-021-04603-y","article-title":"Outcomes of Richter\u2019s transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): an analysis of the SEER database","volume":"100","author":"Elnair","year":"2021","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104551_bib15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.14700","article-title":"An update for richter syndrome-new directions and developments","volume":"178","author":"Eyre","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"18","key":"10.1016\/j.critrevonc.2024.104551_bib16","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/blood-2013-11-536169","article-title":"Correlation between FDG\/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia","volume":"123","author":"Falchi","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104551_bib17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.5060","article-title":"Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia","volume":"245","author":"Garc\u00eda-Barchino","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2024.104551_bib18","article-title":"Plasmablastic lymphoma with coexistence of chronic lymphocytic leukemia in an immunocompetent patient: a case report and mini-review","volume":"2017","author":"Hatzimichael","year":"2017","journal-title":"Case Rep. Hematol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104551_bib19","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2024.104551_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.24841","article-title":"CLL progression after one cycle of FCR: Richter\u2019s transformation versus EBV-associated lymphoproliferation","volume":"92","author":"Jain","year":"2017","journal-title":"Am. J. Hematol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104551_bib21","doi-asserted-by":"crossref","first-page":"e253","DOI":"10.1016\/j.clml.2023.05.014","article-title":"Plasmablastic lymphoma: past, present, and future","volume":"23","author":"Kaur","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104551_bib22","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1093\/labmed\/lmad060","article-title":"Plasmablastic transformation of chronic lymphocytic leukemia: a review of literature and report on 2 cases","volume":"54","author":"Khanna","year":"2023","journal-title":"Lab Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104551_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.26755","article-title":"Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104551_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/BLCTT.S231821","article-title":"The evolving role of brentuximab vedotin in classical hodgkin lymphoma","volume":"9","author":"Lai","year":"2019","journal-title":"Blood Lymphat Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104551_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2020.55.1.49","article-title":"HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases","volume":"55","author":"Li","year":"2020","journal-title":"Blood Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2024.104551_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2024.104551_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235816","article-title":"Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment","volume":"13","author":"Marvyin","year":"2020","journal-title":"BMJ Case Rep."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104551_bib28","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104551_bib29","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00277-016-2904-7","article-title":"Refractory plasmablastic lymphoma-a review of treatment options beyond standard therapy","volume":"96","author":"Pretscher","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2024.104551_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006684","article-title":"BCMA CAR-T induces complete and durable remission in refractory plasmablastic lymphoma","volume":"11","author":"Raghunandan","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2024.104551_bib31","first-page":"285","article-title":"Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia","volume":"4","author":"Richter","year":"1928","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2024.104551_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","article-title":"Richter syndrome: pathogenesis and management","volume":"43","author":"Rossi","year":"2016","journal-title":"Semin Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2024.104551_bib33","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104551_bib34","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.critrevonc.2024.104551_bib35","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.3390\/cancers13205141","article-title":"Richter transformation in chronic lymphocytic leukemia: update in the era of novel agents","volume":"13","author":"Tadmor","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.critrevonc.2024.104551_bib36","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2024.104551_bib37","first-page":"348","article-title":"Richter transformation of chronic lymphocytic leukemia in the era of novel agents","volume":"18","author":"Wang","year":"2020","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2024.104551_bib38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842824002944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:22:09Z","timestamp":1734405729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842824002944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":38,"alternative-id":["S1040842824002944"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104551","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104551"}}